Aberrant laminin signaling drives melanocyte dedifferentiation and unveils a tractable therapeutic target in vitiligo.

Summary

The study links ECM remodeling in vitiligo to a switch from dystroglycan–laminin-211 to integrin α3β1–laminin-332 adhesion, driving melanocyte dedifferentiation with cytoskeletal and signaling changes. Pharmacologic interventions, including JAK inhibition, restored differentiation and pigmentation in mouse models and ex vivo human skin, highlighting a tractable, microenvironment-driven therapeutic axis.

Key Findings

• Vitiligo skin shows reduced laminin-211 and increased laminin-332, shifting melanocyte adhesion toward integrin α3β1–laminin-332 interactions.
• This shift correlates with melanocyte dedifferentiation-like changes, Rho–F-actin remodeling, and coordinated Hippo/MAPK/c-Jun signaling alterations with reduced pigmentation.
• Pharmacologic modulation, including JAK inhibition, restored melanocyte differentiation and pigmentation in mouse models and ex vivo human skin, indicating partial reversibility.

Clinical Implications

Therapies that restore laminin-211 interactions or inhibit the dedifferentiation pathway (including JAK inhibitors) could complement immune-targeted treatments to repigment vitiligo. Biomarkers of ECM remodeling may stratify patients for microenvironment-targeted approaches.

Limitations

• Human sample size and heterogeneity are not fully detailed, and clinical translation requires validation in prospective trials.
• The specific contribution of immune-mediated destruction versus microenvironmental cues in different disease stages remains to be quantified.

Future Directions

Develop ECM- or adhesion-targeted therapeutics and biomarker-guided trials combining JAK inhibitors with microenvironment modulation to enhance repigmentation durability.